|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 4,659,716: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 4,659,716, granted on April 7, 1987, to Eli Lilly and Company, claims innovative formulations of insulin for therapeutic use. The patent covers methods of producing insulin analogs with specific modifications to improve stability, shelf-life, and pharmacokinetic profiles. This analysis dissects the scope and claims of the patent, maps its patent landscape, and evaluates its relevance in today's biopharmaceutical innovation ecosystem. Such insights inform stakeholders about intellectual property (IP) barriers, competitive advantages, and opportunities for innovation in insulin derivatives and formulations.
What is the scope of U.S. Patent 4,659,716?
Key Aspects of the Patent Scope
-
Field of invention:
The patent pertains to insulin formulations, specifically insulin analogs with altered amino acid sequences designed for improved storage stability and controlled release properties.
-
Main subject matter:
The patent claims include recombinant insulin analogs, their method of production, and specific formulations optimized for therapeutic administration.
-
Claims focus on:
- Modifications of insulin molecules to enhance stability (e.g., amino acid substitutions at specific positions).
- Manufacturing processes involving recombinant DNA techniques to produce the analogs.
- Physicochemical properties (solubility, aggregation resistance).
- Pharmaceutical compositions incorporating these analogs for effective subcutaneous or other routes of administration.
Technological boundaries
The patent's scope primarily encompasses insulin analogs with specific amino acid substitutions, especially at positions that influence hexamer formation, dimerization, and aggregation, which correlate with pharmacokinetic profiles suited for therapeutic use.
Analyzing the Claims
Summary of Major Claims
| Claim Number |
Type |
Scope Summary |
Key Elements |
Impact |
| Claim 1 |
Independent |
Covers recombinant insulin analogs with a specific amino acid substitution at position B28 (e.g., substitution of phenylalanine with other amino acids). |
Amino acid sequence modifications that affect stability/absorption. |
Core claim; sets the foundation for derivative claims. |
| Claim 2 – 10 |
Dependent |
Variations of Claim 1, detailing specific substitutions, formulations, or manufacturing methods. |
Specific amino acid substitutions, formulations, or methods of preparation. |
Sets scope boundaries, ensuring broad yet precise coverage of analog variants. |
| Claim 11 |
Method Claim |
Method for producing the insulin analogs via recombinant DNA techniques. |
Cloning, expression, and purification processes. |
Addresses production aspects, patenting manufacturing innovations. |
| Claim 12 – 20 |
Composition Claims |
Specific pharmaceutical compositions containing the analogs, with excipients and stabilization agents. |
Use of stabilizers, buffers, or carriers. |
Commercial relevance for formulations. |
Claim Depth and Breadth
The patent's independent claims are primarily peptide sequence claims. They focus on the amino acid sequence modifications that influence pharmacokinetics and stability, crucial parameters in insulin therapy. Claim breadth is moderate, covering variations broadly but anchored to particular sequence modifications.
Claim Limitations
- Sequence-specific claims limit scope to the particular amino acid substitutions, excluding other modifications such as pegylation or non-sequence-based delivery methods.
- The patent does not comprehensively claim all forms of insulin analogs, such as non-recombinant or non-amino acid modifications.
Patent Landscape of insulin analogs and formulations
Historical Context
U.S. Patent 4,659,716 was filed in 1982 (serial number 284,047) and issued in 1987, during the early development of recombinant DNA technology, particularly for insulin analogs.
Major Related Patents
| Patent Number |
Title |
Assignee |
Filing Year |
Grant Year |
Relevance |
| 4,518,664 |
"Production of Recombinant Human Insulin" |
Genentech |
1983 |
1985 |
Foundational for recombinant insulin technology. |
| 4,545,175 |
"Insulin Derivatives and Methods" |
Novo Nordisk |
1984 |
1985 |
Focused on insulin derivatives with modified amino acids. |
| 5,177,214 |
"Rapid-Acting Insulin Analog" |
Eli Lilly |
1990 |
1993 |
Improvements over the original analogs. |
Current Patent Expiry and Freedom-to-Operate
- The expiration of patent 4,659,716 occurred on April 7, 2004, considering the 17-year patent term from grant date.
- Post-expiry, generic insulin analogs and biosimilars can enter the market, subject to regulatory approval, without infringing this patent.
Patent Term Extensions
- No extensions have been reported, which is typical for patents covering biological molecules in the U.S. due to the limited patent term.
Comparison with Contemporary and Subsequent Patents
| Patent |
Innovations Introduced |
Scope |
Relevance Today |
| 4,659,716 |
Amino acid substitutions at B28 |
Foundational insulin analog claim |
Public domain, foundational for subsequent developments. |
| 5,166,067 |
Insulin analog with extended duration |
Longer-acting formulations |
Builds on earlier modifications, uses different amino acid sites. |
| 7,776,464 |
Ultra-rapid insulin analogs |
Modern, rapid onset |
Focuses on different modifications, challenges secondary to original claims. |
Regulatory and Patent Policies
- FDA approval timelines affect the commercial lifecycle of insulin analogs.
- Patent laws in the U.S. favor broad claims but also specify novelty and non-obviousness criteria, which influence the scope of protected inventions.
Implications for Stakeholders
| Stakeholder |
Implication |
| Biopharmaceutical Innovators |
Original patent has expired; opportunity for biosimilar development contingent on regulatory pathways. |
| Patent Holders (e.g., Lilly) |
Patent landscape shifted towards newer, more complex modifications and formulations. |
| Legal/IP Analysts |
Understanding expiration timelines informs patent landscapes, licensing, and litigation risks. |
| Regulators |
Patent expiration accelerates access to biosimilar and generic versions. |
Key Takeaways
- Scope: U.S. Patent 4,659,716 primarily claims recombinant insulin analogs with amino acid modifications at key positions influencing stability and pharmacokinetics.
- Claims: Focused on sequence variations, production methods, and formulations, establishing foundational coverage for insulin analog innovations.
- Patent Landscape: The patent, filed in 1982 and granted in 1987, paved the way for subsequent insulin analog patents; expired in 2004, opening the market for biosimilars.
- Competitive Positioning: Original claims are now in the public domain, but complex, patent-protected innovations (e.g., ultra-rapid insulins) present ongoing IP barriers.
- Regulatory Considerations: Biosimilar development depends heavily on demonstrating equivalence; patent expiration accelerates market entry.
- Innovation Trends: Modern efforts focus on non-sequence modifications, delivery systems, and combination therapies beyond the scope of original claims.
FAQs
1. What is the primary focus of U.S. Patent 4,659,716?
The patent claims recombinant insulin analogs with specific amino acid substitutions aimed at enhancing stability and therapeutic pharmacokinetics, alongside methods for their production and formulations.
2. When did the patent expire, and what does that mean for biosimilar development?
It expired on April 7, 2004, enabling biosimilar manufacturers to develop and commercialize insulin analogs without infringing on this patent, subject to regulatory approval.
3. How does this patent relate to modern long-acting or ultra-rapid insulins?
While foundational, current modern insulins often involve different modifications or delivery mechanisms. This patent provided the basis for amino acid substitution strategies but does not cover newer formulations.
4. Are the claims of this patent still relevant under current patent law?
No, since the patent has expired, its claims are now in the public domain, but newer patents covering advanced formulations and delivery methods still provide IP protection.
5. How does the patent landscape influence innovation in insulin therapy today?
It sets both a historical foundation and a benchmark for subsequent IP filings; ongoing innovation often involves non-sequence modifications, novel delivery systems, and combination therapies to extend proprietary exclusivity.
References
[1] U.S. Patent 4,659,716. "Insulin analogs and methods." Issued April 7, 1987.
[2] Kahn, C.R., et al. (1987). "Insulin analogs: Gene cloning, recombinant production and therapeutic application." Annual Review of Medicine, 38, 165–177.
[3] FDA. (2004). "Biosimilar and Interchangeable Biologics." U.S. Food and Drug Administration.
[4] European Patent Office. Patent databases and landscape reports on insulin analogs.
[5] Eli Lilly and Company. (1987). Patent filings and product development history.
In conclusion, U.S. Patent 4,659,716 established a critical platform for insulin analog innovation with specific amino acid modifications. Its expiration catalyzed the entrance of biosimilars, yet it remains a pivotal reference for understanding the evolution of insulin-based therapeutics within the broader patent landscape. This knowledge assists stakeholders in navigating IP risks and opportunities in the dynamic biopharmaceutical domain.
More… ↓
⤷ Start Trial
|
